# Beam Therapeutics Inc.: Form 10-Q for the period ended Sep 30, 2021

- Company: [Beam Therapeutics Inc.](/companies/beam.md) (CIK 1745999)
- Form: 10-Q
- Filed: 2021-11-08
- Accepted by EDGAR: Nov 8, 2021, 08:31 ET
- Period: 2021-09-30
- Accession: 0000950170-21-003317
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1745999/000095017021003317/beam-20210930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1745999/000095017021003317/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $763.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2021-01-01 to 2021-09-30 | $775.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2021-07-01 to 2021-09-30 | $54.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2021-01-01 to 2021-09-30 | $290.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | −$69.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | −$329.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | −$28.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | −$305.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.42 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | −$4.86 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.42 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-09-30 | −$4.86 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 66,377,611 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-09-30 | 62,960,219 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | −$68.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2021-01-01 to 2021-09-30 | $33.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-09-30 | $612.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $941.4m | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $1.16bn | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $101.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $302.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-09-30 | $853.8m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1745999/000095017021003317/beam-20210930.htm

Filed Nov 8, 2021.
Source: SEC EDGAR, the filing index for accession 0000950170-21-003317. Last ingested by Listed: Nov 14, 2026, 12:58 ET. No prices; not investment advice.
